Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer

Sellahewa, Chaminda; Carmichael, Amtul R.

doi:10.1186/1477-7800-5-2

Cited by 7 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, these authors acknowledge the difficulties in extricating the effects of childhood body size from correlated adult body size with breast cancer risk. Similarly, as for risk, BMI is associated with prognosis [ 6 - 8 ]. Recent evidence suggests that excess body fat promotes the growth of breast tumors, with worse survival outcomes [ 6 - 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, as for risk, BMI is associated with prognosis [ 6 - 8 ]. Recent evidence suggests that excess body fat promotes the growth of breast tumors, with worse survival outcomes [ 6 - 8 ]. In our study, we cannot exclude the possibility that age at menarche could be an intermediary in the association between childhood BMI and prognosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Breast cancer is a complex and heterogeneous disease and has become a challenging health issue confronted by women worldwide [ 1 , 2 ]. Previous studies have indicated that obesity is one of the risk factors for postmenopausal women with BC; in addition, weight gain is associated with poor prognosis of premenopausal BC [ 3 , 4 ]. However, the exact pathogenesis of obesity in the occurrence and development of BC is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Association of two obesity-related gene polymorphisms LEPG2548A rs7799039 and LEPRQ223R rs1137101 with the risk of breast cancer

et al. 2017

View full text Add to dashboard Cite

Many studies have been performed to investigate the correlation of leptin (LEP) and leptin receptor (LEPR) polymorphisms with breast cancer (BC) risk, however the results are inconclusive. To obtain a more precise estimation, we conducted this meta-analysis. We searched PubMed, EMBASE, and Web of Science databases to identify qualified studies. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the association. Eight eligible studies (2,124 cases and 5,476 controls) for LEP G2548A (rs7799039) polymorphism, and thirteen studies (5,282 cases and 6,140 controls) for LEPR Q223R (rs1137101) polymorphism were included in our study. In general, no significant association between LEP G2548A polymorphism and BC susceptibility was found among five genetic models. In the stratified analysis by ethnicity and sources of controls, significant associations were still not detected in all genetic models. For LEPR Q223R polymorphism, we observed that the association was only statistically significant in Asians (G versus A: OR = 0.532, P = 0.009; GG versus AA: OR = 0.233, P = 0.002; GA versus AA: OR =0.294, P = 0.006; GG versus AA+AG: OR =0.635, P = 0; GA+GG versus AA: OR = 0.242, P = 0.003), but not in general populations and Caucasians. In conclusion, LEP G2548A polymorphism has no relationship with BC susceptibility, while LEPR Q223R polymorphism could decrease BC risk in Asians, but not in overall individuals and Caucasians. More multicenter studies with larger sample sizes are required for further investigation.

show abstract

“…Patients with HER2-positive breast cancer in combination with obesity have a poor prognosis. Thus, patients with a high body mass index (BMI) are 2.5 times more likely to die of breast cancer within five years compared to patients with a low BMI [28]. It should be noted that the in Russia the adult population with obesity is about 30% and 25% of people have overweight.…”

Section: Introductionmentioning

confidence: 99%

Pharmacoeconomic analysis of trastuzumab application for subcutaneous administration compared to intravenous administration in the treatment of HER2-positive breast cancer in regions of the Russian Federation

Kulikov¹,

Nikolaev²,

Kudryavtsev³

et al. 2016

Pharmacoeconom T&P

View full text Add to dashboard Cite

Breast cancer is a malignant neoplasm that develops from the epithelial cells of ducts and lobules of the glandular parenchyma, which according to the World Health Organization (WHO) is the most common form of cancer among women (16% of all cases) in the world. In 2014, in Kaluga, Lipetsk, Smolensk and Tula regions the mortality from breast cancer reached 3.2%, 3.1%, 4% and 4.7%, respectively. One of the aggressive forms of breast cancer is a HER2positive (HER2+) subtype (14 to 20% of all subtypes), which is treated with targeted therapy. The appearance of trastuzumab for subcutaneous administration has a number of advantages compared to the intravenous formulation. A pharmacoeconomic analysis of treatment of HER2+ breast cancer was performed by comparing trastuzumab in two formulations in Kaluga, Lipetsk, Smolensk and Tula regions. According to the "cost minimization" analysis in the analyzed regions, the use of trastuzumab for subcutaneous administration compared to intravenous administration saves from 29.7 to 34% of funds. The forecasted budget savings as a result of the budget impact analysis for 10 patients is 8,068,360 rubles in Kaluga region, 7,047,430 rubles in Lipetsk region, 6,534,750 rubles in Smolensk region, and 7,188,980 rubles in Tula region for the treatment course with trastuzumab in subcutaneous formulation as compared to the intravenous formulation. The results showed that the use of trastuzumab therapy in the subcutaneous formulation allows treatment of 4 additional patients with HER2+ breast cancer in Smolensk region, and 5 patients in Kaluga, Lipetsk and Tula regions within a fixed budget.

show abstract

Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer

Cited by 7 publications

References 16 publications

The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

Association of two obesity-related gene polymorphisms LEPG2548A rs7799039 and LEPRQ223R rs1137101 with the risk of breast cancer

Pharmacoeconomic analysis of trastuzumab application for subcutaneous administration compared to intravenous administration in the treatment of HER2-positive breast cancer in regions of the Russian Federation

Contact Info

Product

Resources

About